Tag: Takeda

EC Approved Takeda’s ADCETRIS 

ADCETRIS in Combination with AVD (Adriamycin, Vinblastine and Dacarbazine) Demonstrated 29-Percent Reduction in the Risk of Progression, Death or Need for Additional Anticancer Therapy for CD30+ Stage...

Takeda’s Dengue Vaccine Met Endpoint in Phase III

Japanese pharma company Takeda has announced that its dengue vaccine candidate TAK-003 met its primary efficacy endpoint in a Phase III trial. Data from the Tetravalent Immunization against Dengue ...

Lonza Reaches Milestone with Takeda

Lonza has reached a major milestone in its multiproduct partnership with Takeda Pharmaceutical Co. Takeda was granted marketing authorization by the European Commission for ALUNBRIG (brigatinib) as a ...

Takeda & Shire Accomplished Merger

Takeda Pharmaceutical Company Limited on January, 8 announced the completion of its acquisition of Shire plc, becoming a global, values-based, R&D-driven biopharmaceutical leader headquartered in ...

Takeda to Develop Novel CAR-T Products

Takeda is upping its commitment to cancer after its Shire takeover with the announcement of three new research collaborations in immuno-oncology. In the first deal, Takeda will collaborate with Mem...

Takeda entered into drug discovery collaboration with Cardiff University

Cardiff University (Wales, UK) has formed a drug discovery collaboration with Takeda to identify new approaches for treating schizophrenia and other psychiatric disorders.

Takeda licenses Humanobodies developed by Crescendo Biologics

Crescendo Biologics (Cambridge, UK), announced that Takeda Pharmaceutical Company Limited (Japan) has exercised an option under its existing, multi-target collaboration and license agreement.

Enterome signs a global agreement with Takeda

Enterome, a clinical-stage biotech company, has entered into a global licensing, co-development and co-promotion agreement with Takeda Pharmaceutical Company Limited.

Takeda and Molecular Templates will jointly develop engineered toxin bodies

Molecular Templates and Takeda announced an agreement for the joint development of CD38-targeted engineered toxin bodies (ETBs) for the treatment of patients with diseases such as multiple myeloma.

Takeda will support the development of Ambys Medicines transformative therapies

Ambys Medicines and Takeda Pharmaceutical Company announced that they have entered into a partnership to support the advancement of the Ambys platform and pipeline.

Takeda launches production of the Ixazomib in Yaroslavl

The global pharmaceutical company Takeda announces the opening of a production site at its plant in Yaroslavl for manufacturing Ixazomib, an innovative drug for patients with multiple myeloma.

Takeda and Celgene invest in Presage Biosciences

Presage Biosciences, a cancer biotechnology company pioneering the use of intratumoral microdosing, announced that it has closed a Series D financing led by pharmaceutical companies Takeda and Celgene.

Takeda held the grand opening of its Global Headquarters in Tokyo

takeda hq tokyo
Takeda Pharmaceutical Company Limited held the grand opening of Takeda Global Headquarters in Tokyo, Japan. The building, completed in March 2018, will serve as Takeda's head office for its operations worldwide.

Takeda produced three pilot batches of Actovegin as part of drug labeling project

Three pilot batches of Actovegin in the total amount of more than 40 thousand packages were produced under the drug labeling project involving the application of special 2D code.

Thermo Fisher signed new agreements with Daiichi Sankyo and Takeda

Thermo Fisher Scientific announced it has signed new agreements with Daiichi Sankyo and Takeda Pharmaceuticals designed to expand the clinical utility of Oncomine Dx Target Test in support of clinical trials and drug development.

Takeda will buy Shire for $64 billion

Japanese drugmaker Takeda has reached a tentative agreement to buy Ireland-based Shire for $64 billion in one of the biggest pharma deals to date.